MX2018013475A - Acido carboxilico para tratar/prevenir congestion nasal. - Google Patents

Acido carboxilico para tratar/prevenir congestion nasal.

Info

Publication number
MX2018013475A
MX2018013475A MX2018013475A MX2018013475A MX2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A
Authority
MX
Mexico
Prior art keywords
carboxylic acid
nasal congestion
pharmaceutically acceptable
acceptable salt
treating
Prior art date
Application number
MX2018013475A
Other languages
English (en)
Spanish (es)
Inventor
Ernst Bettina
Original Assignee
Proponent Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proponent Biotech Gmbh filed Critical Proponent Biotech Gmbh
Publication of MX2018013475A publication Critical patent/MX2018013475A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018013475A 2016-05-17 2017-05-17 Acido carboxilico para tratar/prevenir congestion nasal. MX2018013475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16169882 2016-05-17
PCT/EP2017/061832 WO2017198702A1 (en) 2016-05-17 2017-05-17 Carboxylic acid for treating/preventing nasal congestion

Publications (1)

Publication Number Publication Date
MX2018013475A true MX2018013475A (es) 2019-08-12

Family

ID=56014856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013475A MX2018013475A (es) 2016-05-17 2017-05-17 Acido carboxilico para tratar/prevenir congestion nasal.

Country Status (13)

Country Link
US (1) US20200000751A1 (enExample)
EP (1) EP3458043A1 (enExample)
JP (1) JP6975473B2 (enExample)
KR (1) KR102430892B1 (enExample)
CN (1) CN109152754A (enExample)
AU (1) AU2017266726A1 (enExample)
BR (1) BR112018072177A2 (enExample)
CA (1) CA3020485A1 (enExample)
CL (1) CL2018003270A1 (enExample)
MX (1) MX2018013475A (enExample)
RU (1) RU2018143564A (enExample)
SG (2) SG10202006016QA (enExample)
WO (1) WO2017198702A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11206245B2 (en) * 2009-10-14 2021-12-21 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
US11948678B2 (en) * 2009-10-14 2024-04-02 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
GB202004690D0 (en) * 2020-03-31 2020-05-13 Edinburgh Napier Univ Composition for enhancing immune response of cells
US12414928B2 (en) 2021-05-14 2025-09-16 Rene Dumalaog Javier Viral inactivation spray and gargling formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
CZ301349B6 (cs) * 1997-12-23 2010-01-27 Schering Corporation Prostredek k lécbe respiracních a kožních onemocnení, který obsahuje alespon jednoho antagonistu leukotrienu a alespon jedno antihistaminikum
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
EP1671629A4 (en) * 2003-09-19 2008-11-26 Otsuka Pharma Co Ltd HUMAN BETA DEFENSIN SECRETION AMPLIFIER
US20070256812A1 (en) * 2006-04-19 2007-11-08 Wen-Chen Wei Multidirectional heat dissipating structure
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
CA2886270C (en) * 2012-10-03 2020-04-07 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders

Also Published As

Publication number Publication date
WO2017198702A1 (en) 2017-11-23
BR112018072177A2 (pt) 2019-02-12
CN109152754A (zh) 2019-01-04
JP2019516797A (ja) 2019-06-20
RU2018143564A3 (enExample) 2020-07-23
RU2018143564A (ru) 2020-06-17
SG11201808322PA (en) 2018-10-30
CA3020485A1 (en) 2017-11-23
CL2018003270A1 (es) 2019-02-22
SG10202006016QA (en) 2020-07-29
KR20190009294A (ko) 2019-01-28
AU2017266726A1 (en) 2018-10-11
KR102430892B1 (ko) 2022-08-09
US20200000751A1 (en) 2020-01-02
JP6975473B2 (ja) 2021-12-01
EP3458043A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
JP2010132695A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
NZ714963A (en) Compositions and methods for treating anemia
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
JP2015534562A5 (enExample)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
PH12015502274A1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
MX373699B (es) Composicion farmaceutica que contiene budesonida y formoterol.
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.